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Stressa b s t r a c t
Interleukin-1b is one of the main mediators in the cross-talk between the immune system and the central
nervous system. Higher interleukin-1b levels are found in mood spectrum disorders, and the stress-
induced expression rate of the interleukin-1b gene (IL1B) is altered by polymorphisms in the region.
Therefore we examined the effects of rs16944 and rs1143643 single nucleotide polymorphisms (SNPs)
within the IL1B gene on depressive and anxiety symptoms, as measured by the Brief Symptom Inventory,
in a Hungarian population sample of 1053 persons. Distal and proximal environmental stress factors
were also included in our analysis, namely childhood adversity and recent negative life-events.
We found that rs16944 minor (A) allele specifically interacted with childhood adversity increasing
depressive and anxiety symptoms, while rs1143643’s minor (A) allele showed protective effect against
depressive symptoms after recent life stress. The genetic main effects of the two SNPs were not signifi-
cant in the main analysis, but the interaction effects remained significant after correction for multiple
testing. In addition, the effect of rs16944 A allele was reversed in a subsample with low-exposure to life
stress, suggesting a protective effect against depressive symptoms, in the post hoc analysis.
In summary, both of the two IL1B SNPs showed specific environmental stressor-dependent effects on
mood disorder symptoms. We also demonstrated that the presence of exposure to childhood adversity
changed the direction of the rs16944 effect on depression phenotype. Therefore our results suggest that
it is advisable to include environmental factors in genetic association studies when examining the effect
of the IL1B gene.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Depression has a consistent heritability rate (39%), which sug-
gests a genetic predisposition to the disorder (Kendler and
Prescott, 1999), but biomarker regions of specific genes for depres-
sion have begun to emerge only recently (Cohen-Woods et al.,
2013; Converge-consortium, 2015). Mood disorders are highly
complex clinical conditions with growing number of subcategories
defined by the new DSM-V, and giving an opportunity for clinicians
to refine the existing concepts about mental disorders, e.g. byincluding specifiers like ‘‘with anxious distress” to better distin-
guish between various conditions (AmericanPsychiatricAssocia
tion, 2013). Also in genetic association studies continuous symp-
tom scores are commonly used to assess mood disorder pheno-
types in order to express more precisely the subjects state of
mind, based on the observation that common psychiatric disor-
ders, such as depression, are quantitative traits showing continu-
ous distribution in the population (Plomin et al., 2009). The
importance of using continuous variables was also highlighted by
studies, which demonstrated that different subscales of tools
assessing the state of mood disorder showed different associations
with genetic variants, suggesting that reducing depression and
anxiety state to a simple logistic variable might obscure the iden-
tification of genetic effects (Juhasz et al., 2015).
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known involvement of themonoaminergic pathways, the activation
of inflammatory response has been described in the background of
depression (Dantzer et al., 2011) and other psychiatric conditions
(Michel et al., 2012). Elevated levels of proinflammatory cytokines,
such as IL-1b in depressed individuals, have been confirmed by
meta-analyses (Dowlati et al., 2010; Howren et al., 2009). The
secretion of the IL-1b protein was reported to be dependent on a
functional single nucleotide polymorphism (SNP) rs16944
(NM_0000576.2:c.-598T>C) in the promoter region of IL1B (Hall
et al., 2004). The presence of the minor allele (A), which facilitates
IL-1b production, was associated with elevated risk of depression
in schizophrenic spectrum disorders (Rosa et al., 2004), depressive
symptoms in Alzheimer disease (McCulley et al., 2004) and
depressed state in breast cancer patients (Kim et al., 2013). How-
ever, other studies have shown contradictory results, in that the
A allele was protective against recurrent major depression
(Borkowska et al., 2011), or predicted favourable antidepressant
treatment outcome (Baune et al., 2010; Yu et al., 2003). In addition,
the intronic SNP rs1143643 (NM_000576.2:c.598-152G>A), which
is not in linkage equilibrium with rs16944, was also reported to
influence antidepressant treatment outcome and subgenual ante-
rior cingulated cortex (ACC) activity in the same article (Baune
et al., 2010). Despite these promising findings, no further studies
have investigated the effect of the IL1B gene on mood disorder
phenotypes.
Experiments with laboratory animals showed no significant
effect of the IL-1 family on early brain development, however
robust effects were described when various type of stressors were
present (Alheim and Bartfai, 1998; Giles et al., 2014). Significant
changes were detected in IL-1b expression, for example in
response to chronic pain (del Rey et al., 2012), unpredictable
chronic stress (Ma et al., 2013), repeated social defeat (Wohleb
et al., 2014), and chronic intermittent cold stress followed by acute
immunological challenge (Girotti et al., 2011). Knocking out neces-
sary elements of the IL-1b signalling process resulted in attenuated
stress response in IL-1RI (Wohleb et al., 2014), IL-1 receptor acces-
sory protein (IL-1RAcP) (Laye et al., 2001), and IL-1b converting
enzyme (ICE) (Lawson et al., 2013) gene knock-out models.
Exposure to stress seems to be a crucial mediator in human sub-
jects also. All three studies mentioned above, which identified the
minor A allele of rs16944 as a risk factor in depression, were car-
ried out in patients with other severe medical conditions (Kim
et al., 2013; McCulley et al., 2004; Rosa et al., 2004). By contrast,
in studies finding that the A allele was associated with protective
functions, or better treatment outcome, subjects with other mental
or physical illness were excluded.(Baune et al., 2010; Borkowska
et al., 2011; Yu et al., 2003). While IL-1b has a prominent role in
the comorbidity of depression and physical conditions (Anisman
and Hayley, 2012), such as post-stroke state (Pascoe et al., 2011),
a recent article also reported elevated IL-1b levels in subjects
exposed to psychosocial stress, particularly childhood maltreat-
ment (Hartwell et al., 2013). The effect of different types of stress
and life events, such as the influence of distal and proximal life
stresses on the association of IL1B polymorphisms and depressive
symptoms is yet poorly understood, despite the fact that on many
occasions gene  environment interactions showed greater influ-
ence on mood disorder phenotypes than genetic factors alone
(Juhasz et al., 2015). Moreover a recent review suggested that, con-
sidering the many aspects of cytokines’ effect on the brain, a
broader spectrum of neuropsychiatric conditions might be affected
including neurodegenerative or personality disorders and anxiety
(Capuron and Miller, 2011). Anxiety and depression has a well-
established common genetic diathesis, however it is important to
consider also the differences between them from genetic point of
view, and include both anxiety and depression phenotype ingenetic association analyses which consider novel polymorphisms
or interactions (Pollack, 2005; Scott et al., 2007).
Based on the summarised research results, we hypothesised
that the effects of both rs16944 and rs1143643 polymorphisms
on mood related symptoms are dependent on the presence of life
stressors. To test this hypothesis we analysed gene  environment
interactions, taking into account both proximal (recent negative
life events) and distal life stress (childhood adversity), and com-
pared the interaction effects on depressive and anxiety symptoms.2. Materials and methods
2.1. Population
Phenotypic and genetic data were gathered from volunteers in
Budapest, Hungary during the NewMood study (New Molecules
in Mood Disorders, Sixth Framework Program of the European
Union LHSM-CT-2004-503474). Volunteers, aged between 18 and
60 years, were recruited through advertisement in universities
and at general practices. Participants provided genetic sample
and completed a questionnaire pack. The subjects’ ethnicity,
socio-economic background, medical and psychiatric anamnesis
was assed using a background questionnaire developed and vali-
dated for that study (Juhasz et al., 2009, 2011; Lazary et al.,
2008). Reported medical or psychiatric conditions were not exclu-
sion criteria, since we aimed to investigate a general population
sample. However, in order to avoid stratification bias, our analysis
was performed on non-related individuals with European white
ethnic origin. All participants gave written informed consent
before they entered the study. Our study was approved by the local
ethic committees and was carried out in accordance with the dec-
laration of Helsinki.
2.2. Phenotypes
In our analysis, two phenotypic outcome variables and two
types of environmental stress factors were used. The current
depressive and anxiety state was assessed by the Brief Symptom
Inventory (Derogatis and Melisaratos, 1983) depression and anxi-
ety subscales, with the four additional items included for depres-
sion. Continuous weighted dimension scores were calculated and
used in the analysis.
For interacting factors, we selected confirmed environmental
stressors, namely early life stress and recent negative life stress.
Early life stress was measured by the childhood adversity score
(CHA), which was derived from the Childhood Trauma Question-
naire (CTQ) measuring emotional and physical abuse and neglect
during childhood (Bernstein et al., 1994). An additional question
asked about parental loss during childhood, and added to the total
score. To define recent stressful life events, we used the List of Life
Threatening Experiences questionnaire (Brugha et al., 1985), and
calculated the sum of these events in the past year (Recent nega-
tive Life Events, RLE). In both cases, the sum of item scores was
used in the analysis.
2.3. Genotypes
Buccal mucosa cells were collected from the participants with
cytology brushes, and DNA samples were extracted according to a
published validated method (Freeman et al., 2003). NanoDrop B-
100 spectrophotometerwas used to determine quality and quantity
of DNA. Two SNPswere genotyped in the IL1B gene, namely rs16944
and rs1143643 in the Centre for Integrated Genomic Medical
Research at The University of Manchester using Sequenom Mas-
sARRAY technology (Sequenom Inc., San Diego, CA, USA) under the
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designed by Assay Design 3.0 software of Sequenom, and the iPLEX
assay was performed by the instructions of the manufacturer. The
iPLEX reactionproducts dispendedon384-well SpectroChip (Seque-
nom) were analysed in a Compact Mass Spectrometer by MassAR-
RAY Workstation 3.3 software (Sequenom). Duplicate genotyping
of 15% of random samples showed a 99.87% agreement for
rs1143643, and 99.78% for rs16944.
The selected two SNPs are not in linkage equilibrium and situ-
ated in two distinct haploblocks according to the HapMap project
data (http://hapmap.ncbi.nlm.nih.gov/, (Fig. 1): rs16944 is located
in the functional promoter region and rs1143643 in the intronic
region near to the 30 end.2.4. Statistical analysis
Power calculations with Quanto program (http://biostats.usc.
edu/Quanto.html) were performed before testing, assuming addi-
tive heritability and R2 = 1% explained variance. Our analysis has
86% power in the case of SNP rs16944 and 82% in the case of
SNP rs1143643 to find main genetic effects. With continuous inter-
acting environmental effects represented by CHA and RLE in
Table 1, we have 86% power to detect gene-environment interac-
tion in the case of SNP rs16944 and 83% in the case of SNP
rs1143643.Fig. 1. Linkage disequilibrium map of the IL1B gene.
The LD map of the IL1B gene based on the CEU population data (Utah residents with an
HapMap Project (Phase II. Release 24, 2008). LD R2 values are visualised with the Hapl
programs/medical-and-population-genetics/haploview/haploview).PLINK 1.0.7 (http://pngu.mgh.harvard.edu/purcell/plink) was
used to determine Hardy-Weinberg equilibrium and linkage dise-
quilibrium, and to test additive, dominant and recessive models
in linear regression analysis. Genetic main effects and gene-
environment interactions were tested in separate models. Other
statistical calculations were carried out with IBM SPSS 20.0 for
Windows. Both age and gender of the subjects were used as covari-
ates in all analyses. The nominal significance level was set at
p = 0.05. Bias due to multiple-testing was corrected with the Bon-
ferroni method reducing the significance-threshold to
p = 0.05/36 = 0.001389 (2 SNP-s, 2 phenotypes, 3 heritability mod-
els, 3 types of testing), final threshold a = 1.389  103.
In addition, a Bayesian network based multivariate modelling
method, called Bayesian relevance analysis (Antal et al., 2008),
was carried out in order to further investigate gene-environment
interactions. This method is based on a Bayesian statistical frame-
work (Stephens and Balding, 2009) which relies on Bayesian model
averaging (Hoeting et al., 1999; Madigan et al., 1996) and thus pro-
vides a consistent handling of the multiple hypothesis problem
(Antal et al., 2014). Bayesian relevance analysis computes probabil-
ity scores which quantify the strong relevance of predictors with
respect to a selected target (Hullam and Antal, 2013; Hullam
et al., 2012). For the analysis, discrete phenotypes and environ-
mental factors were used as follows: current depressive and anxi-
ety symptom scores were divided into categorical variables
(low = 0–<1, moderate = 1–<2, severe = 2–4), RLE and CHA scorescestry from northern and western Europe) that were released at the International
oView 4.2 software (https://www.broadinstitute.org/scientific-community/science/
Table 1







Manic episode/disorder 18 1.70%
Obsessive-compulsive disorder 23 2.20%




Eating disorder 72 6.80%
Drug/alcohol problem 24 2.30%
Minimum Maximum Mean SEM
Age 18 60 31.21 1.54
Depression score 0 4 0.554 0.683
Anxiety score 0 4 0.689 0.704
CHA 0 15 2.731 2.921
RLE 0 8 1.083 1.170
Depressive and anxiety symptom scores were measured by the Brief Symptom
Inventory (BSI). CHA – Childhood Adversity; RLE – Recent negative Life Events; SEM
– standard error of mean.
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high = 3 or more; and CHA: low = 0–3, medium = 4–6, high = 7 or
more) based on our previous studies (Lazary et al., 2008).
3. Results
3.1. General information and main effects of the polymorphisms
The total number of participants was 1093, but excluding non-
Caucasian subjects and blood relatives, our analysis was restricted
to 1053 subjects. Due to missing or low quality DNA, genetic sam-
ples of 999 subjects were genotyped. Genotyping success rate was
98.2% for rs16944, and 88.6% for rs1143643. Due to missing pheno-
typic data, the actual analysis was performed on 907 and 832 sub-
jects, for rs16944 and rs1143643 respectively. Description of the
study population can be seen in Table 1.
The two tested SNPs of the IL1B gene were in Hardy-Weinberg
equilibrium, (rs16944: p = 0.52, rs1143643: p = 0.60), and not in
linkage (R2 = 0.227, D = 0.856) in our sample. The experienced
minor allele frequencies (MAF) were consistent with the HAPMAP
CEU (http://hapmap.ncbi.nlm.nih.gov) MAF values (A allele of
rs16944: HAPMAP CEU: 0.358, measured: 0.334; and A allele of
rs1143643: HAPMAP CEU: 0.392, measured: 0.379). Pearson corre-
lation of the interacting factors CHA and RLE was significant, but
acceptably low (Pearson correlation R: 0.119, p = 0.00).
We could not identify significant stress-independent main
effects of the two SNPs on the measured phenotypes (Table 2),
not even with nominal significance threshold. However, both of
the mood disorder phenotypes were affected by the interaction
of our SNPs with CHA and RLE as shown in Table 2.
3.2. Interactions of rs16944 with Childhood Adversity and Recent Life
Events
3.2.1. Depressive symptoms
The A allele carriers scored significantly higher on BSI depres-
sion scale if they were exposed to CHA (Fig. 2A). This interaction
was present in all three inheritance models, and remained signifi-
cant according to the Bonferroni corrected threshold except in the
recessive model. In contrast, higher RLE influenced BSI depression
score at nominal significance level in A allele carriers only ifadditive inheritance was assumed. However this interaction did
not meet the criterion of Bonferroni corrected significance thresh-
old (Table 2).
3.2.2. Anxiety symptoms
Anxiety symptom score was elevated by the A allele-CHA inter-
action similarly to depressive symptoms (Fig. 2B). The significance
of this interaction met the Bonferroni corrected threshold in all
three inheritance models. However the interaction with RLE was
only significant at nominal levels in the additive and dominant
models, but none of them survived Bonferroni correction for mul-
tiple testing (Table 2).
The effect of the CHA-rs16944 A allele were stronger on anxiety,
compared to depressive symptoms, in all inheritance models.
3.3. Interactions of rs1143643 with Childhood Adversity and Recent
Life Events
3.3.1. Depressive symptoms
The interaction of SNP rs1143643 and CHA did not influence
depression scores significantly, even at nominal levels. However
the protective effect of the A allele in interaction with RLE showed
high significance in the dominant heritability model, which met
the Bonferroni corrected threshold; nominal significance was also
detected using additive model (Fig. 3).
3.3.2. Anxiety symptoms
The A allele interaction with CHAwas protective against anxiety
symptoms in both additive and dominant heritability models with
nominal significance, but did not survive Bonferroni correction.
RLE interactions had no effect on anxiety symptoms at any signif-
icance level (Table 2).
In order to test whether the effect of these SNPs can be reversed
by the exposure to life stress, we carried out post hoc genetic main
effect association analysis on depressive and anxiety symptom
scores, in the subgroups of our population sample who had the
lowest scores on RLE and CHA respectively.
3.4. Post-hoc tests of the effects of SNPs in those with low Childhood
Adversity scores
As represented above, for the main tests we had 907 and 832
subjects with sufficient data to carry out the analysis for rs16944
and rs1143643 respectively. Genetic association analysis with
PLINK program for main effects of the SNPs on BSI depression
and anxiety phenotype was carried out on the restricted sample
of 645 and 594 subjects who scored low (0–3) on CHA using the
same methods as in the main testing. Assuming recessive heritabil-
ity, the rs16944 A allele had nominally significant protective effect
against depressive symptoms but no other associations were iden-
tified between the two SNPs and the measured mood disorder phe-
notypes (Table 3).
3.5. Post-hoc tests of the effects of polymorphisms in those with low
Recent Life Event scores
A total of 639 subjects (for rs16944) and 586 subjects (for
rs1143643) were eligible for post hoc testing, after restricting the
population samples to those subjects who reported one or less neg-
ative life events in the past year. Linear regression analysis
between the two SNPs and the two outcome variables, (namely
BSI depressive and anxiety symptom scores) found one significant
association in subjects with the lowest scores. SNP rs16944 A allele
showed protective function against depressive symptoms in the
recessive heritability model (Table 3).
Fig. 2. The effect of interactions between SNP rs16944 and Childhood Adversity, on Depression (A) and Anxiety (B) symptom scores.
Homozygote and heterozygote A allele carriers of the SNP rs16944 showed increased depressive and anxiety symptom scores measured by the Brief Symptom Inventory (BSI)
depending on the exposure of Childhood Adversity (CHA). In the case of depressive symptoms, the AA genotype was protective in those who had low (0–3) CHA scores which
suggest a qualitative interaction. The vertical axis represents the weighted dimension score of BSI depressive and anxiety symptom scores respectively, from the different
groups of subjects, sorted by the exposure to CHA, which was measured by the shortened version of Childhood Trauma Questionnaire (Juhasz et al., 2011). The solid, dotted
and dashed lines indicate the carriers of various genotypes of SNP rs16944.
Table 2
Main effects and interactions with life stress of SNPs rs16944 and rs1143643 on depressive and anxiety symptom scores.
ADD DOM REC
b SEM p value b SEM p value b SEM p value
Depressive symptom score
rs16944 Main effect 0.009 0.035 0.787 0.048 0.047 0.3 0.079 0.074 0.285
CHA interaction 0.052 0.012 1.61  105 0.057 0.018 1.60  104 0.079 0.028 4.34  103
RLE interaction 0.062 0.029 0.031 0.071 0.039 0.064 0.103 0.059 0.08
rs1143643 Main effect 0.018 0.036 0.61 0.021 0.05 0.679 0.029 0.069 0.676
CHA interaction 0.022 0.012 0.078 0.032 0.017 0.054 0.015 0.023 0.512
RLE interaction 0.063 0.03 0.038 0.151 0.04 1.80  104 0.091 0.062 0.141
Anxiety symptom score
rs16944 Main effect 0.035 0.035 0.315 0.068 0.047 0.147 0.013 0.075 0.868
CHA interaction 0.059 0.012 1.91  106 0.061 0.015 8.89  105 0.103 0.028 2.76  104
RLE interaction 0.066 0.029 0.022 0.077 0.039 0.049 0.105 0.06 0.079
rs1143643 Main effect 0.032 0.036 0.381 0.035 0.051 0.494 0.053 0.07 0.449
CHA interaction 0.03 0.013 0.016 0.041 0.017 0.018 0.03 0.024 0.207
RLE interaction 0.019 0.03 0.533 0.06 0.041 0.139 0.061 0.062 0.326
Depressive and anxiety symptom scores were measured by Brief Symptom Inventory (BSI). SEM – Standard error of mean; ADD, DOM, REC – additive, dominant and recessive
heritability models, respectively.
100 D. Kovacs et al. / Brain, Behavior, and Immunity 56 (2016) 96–104
Fig. 3. The effect of interactions between SNP rs1143643 and Recent negative Life
Events, on Depressive symptom score.
Among those people who had self-reported negative life events in the previous
year, rs1143643 minor A allele carriers had lower depressive symptom scores than
non-carriers, representing a protective effect. The figure demonstrates the signif-
icant dominant heritability model; GG represents GG genotype carriers of the
rs1143643 polymorphism, while the homozygote and heterozygote A allele carriers
were collapsed into one group and called AA_AG. The vertical axis represents the
achieved weighted dimension score of the Brief Symptom Inventory’s depressive
symptoms. On the horizontal axis, the Recent negative Life Events (RLE) score is
shown, measured by the Threatening Life Events questionnaire (Brugha et al.,
1985), summarising the stressful events that had happened in the previous year.
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has weak protective effect in both CHA and RLE low scoring sub-
jects against depressive symptoms but not against anxiety symp-
toms. Rs1143643 showed no effect on mood disorder phenotypes
regardless of which life stress factor was excluded.3.6. SNP  SNP interaction and haplotype analysis
During the post hoc testing, we performed SNP  SNP interac-
tion testing. However, we could not identify any significant effects
on depressive (p = 0.684) or anxiety (p = 0.722) symptom scores.
These results further emphasised that the effect of SNPs within
the IL1B gene are dependent on the impact of life stress.
Indeed, haplotype association analysis to test the effects of all
possible haplotypes interacting with life events, demonstrated aTable 3
The effects of SNPs rs16944 and rs1143643 on depressive and anxiety symptom scores in
(RLE).
Low-scored groups to childhood adversity (CHA)
Depressive symptom score ADD
b SEM p value b
rs16944 0.050 0.034 0.134 0.
rs1143643 0.016 0.029 0.581 0.
Anxiety symptom score ADD
b SEM p value b
rs16944 0.037 0.037 0.313 0.
rs1143643 0.014 0.035 0.682 0.
Low-scored groups to recent negative life events (RLE)
Depressive symptom score ADD
b SEM p value b
rs16944 0.045 0.037 0.218 0.
rs1143643 0.008 0.033 0.808 0.04
Anxiety symptom score ADD
b SEM p value b
rs16944 0.011 0.038 0.776 0.00
rs1143643 0.005 0.036 0.880 0.
Depressive and anxiety symptom scores were measured by Brief Symptom Inventory. S
heritability models.highly significant haplotype interaction of the GA haplotype
(rs1143643 and rs16944 respectively) with CHA, conferring risk
for higher depressive (p = 1.65  106) and anxiety (p = 2.51  1
07) symptomscores.Threeadditional significanthaplotype interac-
tionswere also foundwith CHA. However, no associationwas found
of haplotypic main effects or interactions with RLE. Table 4
3.7. Replication of the main significant results after random splitting
the population sample
We also re-ran the analysis on two randomly generated sub-
groups of our population sample, in order to replicate our main
findings which survived Bonferroni correction. The power for find-
ing gene-environment interactions with both CHA and RLE reduced
from 86% to 58% for rs16944, and from 83% to 58% for rs1143643,
as determined by the Quanto program using the same setting as
described earlier. The interaction of re16944 with CHA was found
to influence both depressive and anxiety symptom scores in both
subgroups, with the exception of the recessive heritability model
in sub-group 1 (Depressive symptoms: Group 1: ADD
p = 1.61  102 b = 0.044. DOM p = 2.22  102 b = 0.051. REC
p = 0.366 b = 0.041. Group 2: ADD p = 3.31  104 b = 0.056. DOM
p = 2.59  103 b = 0.061. REC p = 5.33  103 b = 0.097 Anxiety
symptoms: Group 1: ADD p = 1.15  102 b = 0.047. DOM
p = 1.46  102 b = 0.056. REC p = 0.317 b = 0.047. Group 2: ADD
p = 6.61  105 b = 0.064. DOM p = 2.59  103 b = 0.063. REC
p = 2.46  104 b = 0.132). For the interaction of RLE with
rs1143643, using dominant heritability model, significant effect
on depressive symptom was detected only in sub-group 2 (Group
1: DOM p = 0.069 b = 0.095; Group 2: DOM p = 6.90  103
b = 0.133). However, in both groups the direction of effect was
protective, similar to the main analysis. This suggests that the lack
of sufficient significance levels in the first sub-group might be the
result of the reduced statistical power.
3.8. Bayesian relevance analysis of IL1B SNPs in various Childhood
Adversity and Recent Life Events exposure groups
Bayesian relevance analysis was carried out in each of the CHA
and RLE exposure groups separately. Results indicated thatthe low-scored groups to Childhood Adversity (CHA) and Recent negative Life Events
DOM REC
SEM p value b SEM p value
024 0.045 0.600 0.168 0.071 0.019
021 0.042 0.612 0.022 0.057 0.706
DOM REC
SEM p value b SEM p value
03 0.05 0.542 0.092 0.078 0.238
018 0.050 0.725 0.021 0.068 0.753
DOM REC
SEM p value b SEM p value
011 0.049 0.822 0.184 0.079 0.021
7 0.047 0.315 0.060 0.065 0.357
DOM REC
SEM p value b SEM p value
7 0.051 0.892 0.07 0.083 0.4
006 0.050 0.908 0.009 0.070 0.895
EM – Standard error of mean; ADD, DOM, REC – additive, dominant and recessive
Table 4
The effect of the interaction, between IL1B haplotypes and Childhood Adversity and Recent negative Life Events, on depressive and anxiety symptom scores.
HT1: AA HT2: GA HT3: AG HT4: GG
1.25% 32.61% 36.42% 29.72%
b SEM p value b SEM p value b SEM p value b SEM p value
Depressive symptom score Main effect 0.210 0.159 0.188 0.011 0.037 0.771 0.008 0.037 0.824 0.009 0.038 0.805
CHA interaction 0.099 0.06 0.096 0.06 0.012 1.65  106 0.019 0.013 0.132 0.036 0.012 0.003
RLE interaction 0.087 0.129 0.501 0.055 0.031 0.073 0.06 0.031 0.052 0.008 0.03 0.801
Anxiety symptom score Main effect 0.3 0.161 0.062 0.057 0.038 0.131 0.016 0.038 0.662 0.025 0.038 0.52
CHA interaction 0.082 0.061 0.181 0.066 0.013 2.51  107 0.029 0.013 0.024 0.032 0.013 0.011
RLE interaction 0.027 0.13 0.836 0.055 0.031 0.076 0.014 0.031 0.646 0.04 0.03 0.183
The first and second letter in the haplotypes indicates the allele of rs1143643 and rs16944 respectively. CHA: Childhood Adversity score. RLE: Recent negative Life Events
score. Depressive and anxiety symptom scores were measured by Brief Symptom Inventory. SEM – Standard error of mean.
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the highest scoring CHA group with a moderately high posterior
probability (0.48), whereas in the low (0.03) and medium (0.07)
scoring groups it was non-relevant (Table 5). In the case of anxiety
symptoms, a similar phenomenon could be observed; SNP rs16944
had a moderately high posterior probability for strong relevance in
the highest scoring CHA group (0.50), contrary to the low posterior
probability of medium (0.10) and low (0.01) scoring groups. Fur-
thermore, rs1143643 had a similar trend with respect to depres-
sive symptoms with the posterior probability of strong relevance
given the highest scoring RLE group was considerably greater
(0.85) than the low (0.04) and medium (0.12) groups. In contrast,
rs1143643 was non-relevant with respect to anxiety symptoms
for all RLE groups. In summary, the relevance of the polymor-
phisms for both symptom scores was consequently higher in the
more exposed groups compared to the less exposed ones.4. Discussion
Our study demonstrated that two polymorphisms of the IL1B
gene interacted in different ways with Childhood Adversity
(CHA) and Recent negative Life Events (RLE) affecting depressive
and anxiety symptoms. Rs16944, which is a functional SNP in the
promoter region, showed multiple-testing corrected significant
interactions with CHA, with the A allele increasing both depressive
and anxiety symptom scores, with stronger effect on anxiety, while
RLE interactions could not met the Bonferroni corrected threshold.
The rs16944-CHA interaction was also replicated when we ran-
domly split our cohort into two sub-groups, in the additive and
dominant heritability models. In contrast to this effect
rs1143643, which is an intronic SNP at the 30 end of the gene,
showed interaction with RLE with the minor A allele exerting pro-
tective effect against depressive but not against anxiety symptomsTable 5
Posterior probability of strong relevance for rs16944 and rs1143643 with respect to
depressive and anxiety symptom scores in various Childhood Adversity (CHA) and
Recent negative Life Events (RLE) exposure groups.
SNP Target Childhood Adversity
Low Medium Severe
rs16944 Depression 0.03 0.07 0.48
Anxiety 0.01 0.1 0.5
rs1143643 Depression 0.01 0.09 0.35
Anxiety 0.01 0.05 0.52
SNP Target Recent life events
Low Medium Severe
rs16944 Depression 0.05 0.39 0.52
Anxiety 0.02 0.05 0.16
rs1143643 Depression 0.04 0.12 0.85
Anxiety 0.03 0.04 0.16at a Bonferroni corrected significance level. However, this RLE
interaction of rs1143643 was only partially replicated in the ran-
domly split sub-groups. The results of Bayesian relevance analysis
also confirmed the interaction between rs16944 and CHA with
respect to both depression and anxiety, and also the interaction
between rs1143643 and RLE with respect to depression. In addi-
tion, Bayesian relevance analysis and the negative SNP  SNP
interaction results reinforced the view that the inclusion of envi-
ronmental factors is crucial for association analyses related to
depression phenotypes. Haplotype association analysis, to investi-
gate the effect of the whole IL1B gene, demonstrated a highly sig-
nificant interaction between the GA haplotype and CHA, which
elevated both depressive and anxiety symptom scores, and also
survived the correction for multiple testing. Regarding haplotype
interaction with RLE, only weak trends were observable. These
data suggest a strong, long-lasting effect of CHA on the function
of the IL1B gene, while a much weaker moderating effect of RLE
could not be ruled out and warrants further investigations.
4.1. Rs16944
Our results implicate a bidirectional relationship between life
stress and rs16944 polymorphism. A synergic relationship
between high stress exposure and the minor A allele (causing vul-
nerability to more severe depressive and anxiety symptoms) has
been identified, while in the low-exposed groups a weak protective
function of the A allele was found.
Our results are in line with previous studies that found higher
risk of depression in carriers of the higher synthesizing A allele,
in schizophrenic (Rosa et al., 2004), Alzheimer (McCulley et al.,
2004) and breast cancer patients (Kim et al., 2013). We suggest
that the apparent contradiction between our results and earlier
studies that found the A allele protective against recurrent major
depression (Borkowska et al., 2011) or non-remission in antide-
pressant therapy (Baune et al., 2010; Yu et al., 2003), was due to
the different stress exposure of the examined subject groups, since
our post hoc analysis on both of the low-exposed subgroups (CHA
or RLE) showed the protective effect described by the three studies
above.
Previous studies have demonstrated that risk genes of depres-
sion are frequently associated with advantageous immunological
and behavioural responses to infection (Raison and Miller, 2013).
Thus the protective effect of the A allele in the non-stressed sub-
jects may be explained by better pathogen host defence and thus
better quality of life, while the excessive up-regulation of IL-1b
production during life stress may interfere with normal brain func-
tion and thus create maladaptive behaviour (Dowlati et al., 2010).
The observed interaction in our study was stronger with CHA
than RLE suggesting that rs16944 is likely to exert its effect in early
brain development, resulting in vulnerability to depression
throughout life (Borsini et al., 2015; Semple et al., 2013). Moreover
D. Kovacs et al. / Brain, Behavior, and Immunity 56 (2016) 96–104 103we demonstrated that both anxiety and depression phenotypes
were affected by the life-stress interaction of rs16944, but the pro-
tective effect in the low-exposed groups was found in depression
phenotypes only, suggesting different roles of cytokines in the
development of depression and anxiety (Roy-Byrne et al., 2008).
4.2. Rs1143643
Rs1143643 showed Bonferroni corrected significant interaction
with RLE, but only nominally significant interactions with CHA –
opposite to the findings for rs16944. In addition, the RLE interac-
tion only influenced depressive symptoms (not anxiety symptoms)
providing further support that different underlying mechanisms
might occur in depression compared with anxiety (Pollack,
2005). In line with our results, Baune et al. found that the minor
A allele of the SNP has been associated with better outcome during
antidepressant therapy, namely it protected against non-remission
(Baune et al., 2010). According to the National Institute of Environ-
mental Health Sciences (http://snpinfo.niehs.nih.gov/snpinfo/
snpfunc.htm), this intronic SNP has no evident functional activity,
although HAPMAP states that it is 869 bp from, and in linkage with,
rs1071676 which has been associated with different allelic expres-
sion of the IL1B gene (Serre et al., 2008). As rs1143643 is near to the
30 end of the IL1B gene, it may also affect the stability of the tran-
scripted mRNA which is one of the main mechanisms in adaptation
to stress (Guhaniyogi and Brewer, 2001). The stronger interaction
with RLE compared to CHA suggests that this SNP, or the 30 end
genetic region in linkage with it, has a role in the adaptation to
recent stressors (Dhabhar, 2014). However the results of haplotype
analysis suggest that – at gene level – the effect of CHA could be
more important, and the potential moderating effect of RLE on
the IL1B gene function has a smaller effect size which was not suf-
ficiently robust in our study due to limited power.
4.3. Effects of IL-1b in the central nervous system
IL-1b has been proposed to possess a central role in the cross-
talk between the immune system and the central nervous system
(Baganz and Blakely, 2013). IL-1b modulates tryptophan metabo-
lism by enhancing the activity of the indolamine-2.3-dyoxigenase
(IDO) enzyme, and thus indirectly causes lower tryptophan avail-
ability for serotonin production; IDO also activates the kynurenine
pathway which produces potentially neurotoxic metabolites
(Dantzer et al., 2011). IL-1b has a regulatory role in HPA axis activ-
ity, thus contributing to depression-induced cortisol-resistance
(Maes et al., 1993). Consistently, higher IL-1b activity in the brain
can also influence neural plasticity through microglial activation
(Miller et al., 2009), while kynurenine and the HPA axis also greatly
influence neural plasticity promoting depression-specific changes
in the neural network (Rothwell and Luheshi, 2000). Moreover,
proinflammatory cytokines, such as IL-1b, have been suggested to
play an important role in the internalization of social-
environmental stress (including childhood trauma and life stress
in adulthood) (Slavich and Irwin, 2014).
4.4. Strength and limitations
Our study is the first that systematically investigated different
parts of the IL1B gene in interaction with early and recent life stres-
sors on mood disorder related symptoms; for example, this is the
first time that the anxiogenic effect of rs16944’s life stress interac-
tions has been demonstrated. Also the main results were con-
firmed by two entirely different statistical methods – linear
regression analysis and Bayesian relevance analysis. However,
our study has some limitations. First, our analysis was limited to
only two polymorphisms based on previous articles (Baune et al.,2010; Borkowska et al., 2011; Yu et al., 2003). Second, our popula-
tion sample was relatively small and consists mostly of female sub-
jects. Third, we used childhood adversity and recent negative life
events as known environmental risk factors but other aspects of
interactions such as comorbid diseases or social support were
not included in our analysis. Fourth, the risk factors and pheno-
types were self-reported by questionnaires, which might bias our
variables. Fifth, after the random splitting of our population sample
we could not replicate some of our findings in the two pseudo-
independent subgroups, possibly because of the reduced statistical
power. And finally, some of our results did not survive correction
for multiple testing, so further replication studies are required to
confirm these findings.
4.5. Conclusions
Our study is the first to provide evidence for the interaction of
rs16944 and rs1143643 polymorphisms of the IL1B gene with dif-
ferent environmental stress factors. Therefore we suggest that fur-
ther investigations of the IL1B gene should also include, in the
analysis, various stress factors (e.g. comorbid disorders, socioeco-
nomic disadvantages, or psychosocial stresses) in order to obtain
a consistent effect of the polymorphisms on mood disorder pheno-
types. Also organizing the polymorphisms effect by environmental
vulnerability can provide us with a better understanding of the role
of the IL1B gene in pathomechanisms of mood spectrum disorders.
Furthermore, analyses carried out in the most exposed groups
show much stronger genetic effects as described earlier with other
genetic variants also (Juhasz et al., 2015, 2014).
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